Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the company at HK$11.2 billion (US$1.4 billion).

Last week, InnoCare Pharma Ltd. (HKEX:9969) initially offered to sell 25 million shares to Hong Kong investors

Read the full 575 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE